pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›giredestrant
drug · small molecule
save

giredestrant

pre_registrationupdated 6mo ago
by Genentech Inc🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 4
  • tagOncology2 co-mentions · 1 sources
  • tagBreast Cancer2 co-mentions · 1 sources
  • drugtrastuzumab biosimilar1 co-mentions · 1 sources
  • drugtrastuzumab1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.

indications

indications
Breast Cancer

targets

Estrogen receptor

all catalysts(0)

nothing on the calendar yet

Trials studying giredestrant

  • phase3A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)recruitingn=300
  • phase3A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancernot yet recruitingn=3,800
  • phase2Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumorsrecruitingn=430
  • phase3A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Studyrecruitingn=200
  • phase1A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancernot yet recruitingn=165
  • phase3A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatmentrecruitingn=1,500
  • phase2A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancerrecruitingn=120
  • phase2A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancerrecruitingn=285

News(10)

  • STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more
    The FDA approved a breast cancer drug from Roche, teeing up the launch of what the company has said could become its top-selling product
    stat · 6h ago
  • Roche enters the SERD market with FDA approval in late-stage breast cancer
    Roche’s big-hope breast cancer pill giredestrant was in an odd situation in that it was awaiting two different FDA approval decisions. Also oddly, the second one came first. The drug was
    endpoints · 8h ago
  • STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
    The FDA approved a new breast cancer drug from Roche, teeing up the launch of a medicine the company has said could become its top-selling product ever.
    stat · 23h ago
  • Roche’s changing plans show how MFN is complicating European drug launches
    Roche will seek European approval for its promising new breast cancer pill giredestrant later than it once expected, highlighting how US drug pricing pressure may be affecting pharmaceutical compan…
    endpoints · 22d ago
  • Roche says it will help patients who are 'anxiously awaiting' its new breast cancer drug
    Roche is gearing up for a major launch with its breast cancer pill giredestrant, and according to Teresa Graham, head of the company’s pharma unit, patients are clamoring to get hold of the drug. G…
    endpoints · 26d ago
  • Roche affirms sales outlook amid doubts about its future
    Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.
    biopharma_dive · 26d ago
  • ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
    When recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.
    fiercebiotech · 1mo ago
  • Roche, Ionis RNA drug scores in kidney disease study
    The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.
    biopharma_dive · 1mo ago
  • AstraZeneca’s newly approved pill fails frontline breast cancer study
    Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
    biopharma_dive · 2mo ago
  • FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
    In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new…
    fiercebiotech · 2mo ago
view all news mentions →
generic
giredestrant
MOA
Estrogen receptor alpha degrader
indication
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 7h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?